» Articles » PMID: 39621534

Anemia Risk Prediction Model for Osteosarcoma Patients Post-Chemotherapy Using Artificial Intelligence

Overview
Journal Cancer Med
Specialty Oncology
Date 2024 Dec 2
PMID 39621534
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: This study aimed to develop a machine learning model for predicting anemia post-chemotherapy in osteosarcoma patients.

Methods: Clinical data from 631 osteosarcoma patients were collected, and after data filtering, a training set and validation set were created. Various statistical tests were conducted on the data, and single-factor and multiple-factor logistic regression analysis, random forest (RF), support vector machine (SVM), and least absolute shrinkage and selection operator (LASSO) were used to construct risk prediction models. A new model was created by intersecting the above models to identify common risk factors, and a nomogram was developed to display the new model. The model's performance was validated using the validation set.

Results: Twenty-five risk factors were identified in the anemia group compared to the non-anemia group (p < 0.05). Single-factor logistic regression analysis identified 22 risk factors (AUC 0.895), whereas multiple-factor logistic regression analysis identified 8 risk factors (AUC 0.872), RF identified 7 risk factors (AUC 0.851), SVM identified 16 risk factors (AUC 0.851), and LASSO identified 19 risk factors (AUC 0.902). Five common risk factors (ALB, Ca, CREA, D-dimer, and ESR) were identified through model intersection, yielding a new model with an AUC of 0.85. Internal validation of the new model showed an AUC of 0.802, indicating high predictive ability. A web model application was created (https://anemic-prediction-of-osteosarcoma.shinyapps.io/DynNomapp/).

Conclusion: The developed risk prediction model based on clinical and laboratory data can aid in individualized diagnosis and treatment of anemia in osteosarcoma patients post-chemotherapy.

References
1.
Reinhart W, Nagy C . Albumin affects erythrocyte aggregation and sedimentation. Eur J Clin Invest. 1995; 25(7):523-8. DOI: 10.1111/j.1365-2362.1995.tb01739.x. View

2.
Wautier J, Wautier M . Old and New Blood Markers in Human Colorectal Cancer. Int J Mol Sci. 2022; 23(21). PMC: 9656373. DOI: 10.3390/ijms232112968. View

3.
Song K, Song J, Lin K, Chen F, Ma X, Jiang J . Survival analysis of patients with metastatic osteosarcoma: a Surveillance, Epidemiology, and End Results population-based study. Int Orthop. 2019; 43(8):1983-1991. DOI: 10.1007/s00264-019-04348-4. View

4.
Garcia-Martinez R, Caraceni P, Bernardi M, Gines P, Arroyo V, Jalan R . Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications. Hepatology. 2013; 58(5):1836-46. DOI: 10.1002/hep.26338. View

5.
Lang E, Gatidis S, Freise N, Bock H, Kubitz R, Lauermann C . Conjugated bilirubin triggers anemia by inducing erythrocyte death. Hepatology. 2014; 61(1):275-84. PMC: 4303990. DOI: 10.1002/hep.27338. View